HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch + Lomb Rings Bell On 'Largest' Launch Year

Executive Summary

Canadian firm’s eye health supplements Occuvite and PreserVision remain top sellers, with ReNu and Biotrue contact lens solutions and Lumify eye drops and skin care line rounding out its top 10 revenue generators.

You may also be interested in...



Beauty Part Of Lumify Story For Bausch + Lomb? From Redness Relief To 'Make Eyes Look Beautiful'

Lumify sales up 47% to reported $44m in Q3 as brand and firm’s vision health vitamins Ocuvite and PreserVision remain key drivers for its vision care segment, which also includes contact lenses and solutions.

Bausch + Lomb Patiently 'Semi-Private' While Bausch Health Plots Path To Spin-Out Completion

B+L using period of Bausch Health’s near-full ownership to plan for future. "When the spin comes, then we can spend a lot more time with our investors. But right now, I just have to take the elevator down two floors and I can see the 90% shareholder,” says CEO Brent Saunders.

In J&J’s ‘Mutually Beneficial’ Frame For Selling Blink OTC Eye Drops To B+L, Kenvue Also Wins

In second buy in a week, B+L paying $106.5m in cash deal for products marketed by Johnson & Johnson Vision. Acquired products are Blink Tears lubricating eye drops and Blink Contacts and Blink-N-Clean lens drops.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel